title: Over-the-counter statins.
abstract: In late 2004, the British government decided to allow a lipid-lowering agent to be sold as an over-the-counter medication. In contrast, the U.S. Food and Drug Administration recently decided not to do so. The United States and other countries will soon face similar decisions for other statins. Although statins have infrequent side effects and have been shown to be effective in moderate-risk primary prevention populations, many questions remain unanswered about their effectiveness at lower doses in over-the-counter use, the ability of patients to self-select themselves for appropriate therapy, and the social and economic implications associated with this method of distribution for preventive medications. A rational policy decision concerning over-the-counter statin use will require an effectiveness trial to provide data on how such drugs would be used in this context, as well as on the clinical outcomes that could be expected from this novel "route of administration."
authors.affiliation: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02120, USA.
authors.forename: Niteesh K
authors.initials: NK
authors.lastname: Choudhry
authors.forename: Jerry
authors.initials: J
authors.lastname: Avorn
mesh_terms: D003256:Community Participation; D017277:Drug Approval; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000145:classification* / Q000592:standards; D004366:Nonprescription Drugs / Q000009:adverse effects / Q000145:classification* / Q000592:standards; D012307:Risk Factors; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D004366:Nonprescription Drugs